Tranexamic acid for skin
Last updated:
Tranexamic acid is a synthetic lysine derivative developed as an antifibrinolytic drug that inhibits plasminogen activation. In skincare it is used for pigmentation: instead of inhibiting tyrosinase, it reduces the inflammatory and vascular signaling that stimulates melanocytes, which is why it is often combined with tyrosinase inhibitors. Topical formulations generally run 2% to 5%, and results take months.
What is tranexamic acid?
Tranexamic acid is a synthetic lysine derivative developed as an antifibrinolytic drug - it inhibits plasminogen activation and is used clinically to reduce bleeding. Its pigmentation use came from the observation that plasmin activity contributes to melanogenesis, particularly in melasma.
How does tranexamic acid work?
Most brightening actives inhibit tyrosinase, the rate-limiting enzyme in melanin synthesis. Tranexamic acid does something different: by interfering with the plasminogen–plasmin pathway it reduces the inflammatory and vascular signaling that drives melanocyte stimulation, particularly UV- and hormone-triggered pigmentation.
That difference is clinically useful, because it means tranexamic acid addresses a pathway that tyrosinase inhibitors do not - which is why it is often combined with them rather than substituted for them, and why it performs relatively well in melasma, where inflammation and vascular components are prominent.
What concentration of tranexamic acid do serums use?
Topical formulations generally run 2% to 5%. The Youlief DIA Clear Serum uses 5%, which is the top of the usual range and consistent with the concentrations used in clinical comparisons. This is one of the ingredients in the range where the stated level clearly matches the literature.
What does tranexamic acid not do?
It is not a rapid fix; pigmentation work is measured in months. It does not remove pigment already deposited in the epidermis, so it must be paired with sun protection to show any benefit. And topical use is a different proposition from oral tranexamic acid, which carries thrombotic considerations and belongs entirely with a clinician.
Key takeaways
- Tranexamic acid inhibits plasminogen activation and was developed to reduce bleeding.
- Plasmin activity contributes to melanogenesis, particularly in melasma.
- It works on a pathway that tyrosinase inhibitors do not, so it is often combined with them.
- Topical formulations generally run 2% to 5%; 5% is consistent with clinical comparisons.
- It does not remove pigment already deposited, so sun protection is needed to see any benefit.
References
The studies below describe the ingredient itself. Finished-product results appear in each product's evidence dossier.
- Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation
- Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial
- Tranexamic acid as a therapeutic option for melasma management: meta-analysis and systematic review of RCTs
Frequently asked questions
Is tranexamic acid a tyrosinase inhibitor?
No. Most brightening actives inhibit tyrosinase, the rate-limiting enzyme in melanin synthesis. Tranexamic acid instead interferes with the plasminogen to plasmin pathway, reducing the inflammatory and vascular signaling that drives melanocyte stimulation.
How long does tranexamic acid take to work?
Tranexamic acid is not a rapid fix; pigmentation work is measured in months. It must be paired with sun protection to show any benefit.
Is topical tranexamic acid the same as oral tranexamic acid?
No. Topical use is a different proposition from oral tranexamic acid, which carries thrombotic considerations and belongs entirely with a clinician.
Related reading
More in ingredients
Products containing tranexamic acid
Listed because this ingredient appears in each product's declared composition. This is a commercial link from a reference page; it is not a recommendation, and approved uses and availability vary by market.